Global Bioenergies (GBE) is scaling up its operations as planned ahead of its next important steps to commercialisation. 2015 results are evidence of managed expenses, while capex spend is peaking as the company builds its second demo plant. GBE has also achieved further improvement in isobutene purity, which opens new, higher value-added end markets. We believe the company is on track with its operations and funded through to 2017. Our valuation range remains unchanged at €32-59 per sha
08 Apr 2016
Spend to deliver
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Spend to deliver
Global Bioenergies SA (ALGBE:PAR) | 0 0 1.6% | Mkt Cap: 77.3m
- Published:
08 Apr 2016 -
Author:
Catharina Hillenbrand-Saponar -
Pages:
5
Global Bioenergies (GBE) is scaling up its operations as planned ahead of its next important steps to commercialisation. 2015 results are evidence of managed expenses, while capex spend is peaking as the company builds its second demo plant. GBE has also achieved further improvement in isobutene purity, which opens new, higher value-added end markets. We believe the company is on track with its operations and funded through to 2017. Our valuation range remains unchanged at €32-59 per sha